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REAMBLE
edicine is experiencing an unprecedented focus on quanti-
ying and improving health care quality. The American Col-
ege of Cardiology (ACC) and the American Heart Associa-
ion (AHA) have developed a multi-faceted strategy to
acilitate the process of improving clinical care. The initial
hase of this effort was to create clinical practice guidelines that
arefully review and synthesize available evidence to better
uide patient care. Such guidelines are written in a spirit of
uggesting diagnostic or therapeutic interventions for patients
n most circumstances. Accordingly, significant judgment by
linicians is required to adapt these guidelines to the care of
ndividual patients, and these guidelines can be generated with
arying degrees of confidence based upon available evidence.
ccasionally, the evidence supporting a particular structural
spect or process of care is so strong that failure to perform
uch actions reduces the likelihood that optimal patient out-
omes will occur. Creating a mechanism for quantifying these
pportunities to improve the outcomes of care is an important
nd pressing challenge.
In the next phase of its quality improvement efforts, the
CC and the AHA created the ACC/AHA Task Force on
erformance Measures in February 2000 to spearhead the
evelopment of performance measures that allow the quality of
ardiovascular care to be assessed and improved. Three nom- tnees from each organization were charged with the task of
ssembling teams of clinical and methodological experts, both
rom within the sponsoring organizations and from other
rganizations dedicated to the care of patients covered by the
erformance measurement set. These writing committees were
iven careful guidance with respect to the necessary attributes
f good performance measures and the process of identifying,
onstructing, and refining these measures so that they can
ccurately achieve their desired goals (1).
The role of performance measurement writing commit-
ees is not to perform a primary evaluation of the medical
iterature; this is undertaken by ACC/AHA guidelines
ommittees. However, performance measurement writing
ommittees work collaboratively with guidelines committees
o that the guideline recommendations are written with a
egree of specificity that supports performance measure-
ent and so that new knowledge can be rapidly incorpo-
ated into performance measurement. Development of
CC/AHA guidelines includes a detailed review of and
anking of the evidence available for the diagnosis and
reatment of specific disease areas. Published guideline
ecommendations employ the ACC/AHA classification
ystem I, IIa, IIb, and III (Fig. 1).
So as not to duplicate performance measure development
fforts, writing committees were also instructed to evaluate
xisting nationally recognized performance measures using
he ACC/AHA “attributes of good performance measures.”
he measure specifications were adopted for those perfor-
ance measures that meet these criteria. Such measures
ave established validity, reliability, and feasibility and will
orm the foundation of the ACC/AHA measurement sets.
urthermore, writing committees are encouraged to identify
dditional performance measures that correspond to those
ey areas of quality proven to improve patient outcomes.
ACC/AHA Performance Measurement Sets are to be
pplied in either the inpatient and/or outpatient setting
epending upon the topic. Although inpatient measures
ave traditionally been captured by retrospective data col-
ection, the increased use of electronic medical records
llows for prospective collection in the inpatient and out-
atient settings. Prospective data collection is itself a con-
inuous quality improvement process. The performance
easures quantify explicit actions performed in carefully
pecified patients for whom adherence should be advocated
n all but the most unusual circumstances. In addition, the
easures are constructed with the intent to facilitate both
etrospective and prospective data collection using explicit
dministrative and/or easily documented clinical criteria.
urthermore, the data elements required to construct the
erformance measures are identified and linked to existing
CC/AHA Clinical Data Standards to encourage the
tandardization of cardiovascular measurement.
While the focus of the performance measures writing
ommittees is to develop measures for internal quality im-
rovement, it is appreciated that other organizations may use
hese measures for external reporting of provider performance.
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ACC/AHA STEMI/NSTEMI Performance Measures January 3, 2006:236–65herefore, it is within the scope of the writing committee’s task
o comment on the strengths and limitations of externally
eporting potential performance measures. Specifically, this
as done in the inpatient measurement set, where a “Chal-
enges to Implementation” section was included below the
pecification, when appropriate (see Appendix A).
All the measures contained in this set have limitations and
hallenges to implementation that could result in unintended
onsequences when used for accountability purposes. The
mplementation of these measures for purposes other than
uality improvement (QI) require field testing to address issues
elated to, but not limited to, sample size, reasonable frequency
f use for an intervention, comparability, and audit require-
ents. The way in which these issues are addressed will be
ighly dependent on the type of accountability system devel-
ped including data collection method, assignment of patients
o physicians for measurement purposes, baseline measure
etting, incentive system, and public reporting method among
thers. The ACC/AHA encourages those interested in work-
ng on implementation of these measures for purposes beyond
*Data available from clinical trials or registries about the usefulness/efﬁcacy in diﬀere
heart failure, and prior aspirin use. A recommendation with Level of  Evidence B or
addressed in the guidelines do not lend themselves to clinical trials. Even though rand
test or therapy is useful or eﬀective.
† In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of  sugge
have been written in full sentences that express a complete thought, such that a recom
headings above sets of recommendations), would still convey the full intent of the rec
and will allow queries at the individual recommendation level.
Figure 1. ACC/AHA classification oI to work with the ACC/AHA to understand these complexssues in pilot testing projects that can measure the impact of
ny limitations and provide guidance on possible refinements
f the measures that would make them more suitable for
dditional purposes.
In the process of facilitating the measurement of cardio-
ascular health care quality, the ACC/AHA Performance
easurement Sets can serve as a vehicle for more rapidly
ranslating the strongest clinical evidence into practice.
hese documents are intended to provide practitioners with
tools” for measuring the quality of care and for identifying
pportunities to improve. Because the target audience and
nit of analysis for these measures is the practitioner, they
ere constructed from the provider’s perspective and were
ot intended to characterize “good” or “bad” practice but to
e part of a system with which to assess and improve health
are quality. It is our hope that an application of these
erformance measures within a system of QI will provide a
echanism through which the quality of medical care can
e measured and improved.
Robert O. Bonow, MD, FACC, FAHA
-populations, such as gender, age, history of  diabetes, history of  prior MI, history of  
es not imply that the recommendation is weak. Many important clinical questions 
d trials are not available, there may be a very clear clinical consensus that a particular 
hrases to use when writing recommendations. All recommendations in this guideline 
tion, even if  separated and presented apart from the rest of  the document (including 
ndation. It is hoped that this will increase readers’ comprehension of  the guidelines 
mmendations for practice guidelines.nt sub
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he ACC/AHA ST-Elevation and Non–ST-Elevation
yocardial Infarction (STEMI/NSTEMI) Performance
easures Writing Committee was charged with the devel-
pment of performance measures concerning the diagnosis
nd treatment of both ST-elevation myocardial infarction
STEMI) and non–ST-elevation myocardial infarction
NSTEMI) (see the Methodology section for detailed
nformation on how the measures were constructed and
elected.)
. Scope of the Problem
oth STEMI and NSTEMI afflict an enormous number of
eople each year. The estimated incidence of myocardial
nfarction (MI) is 865 000 attacks annually. Twenty percent
f men and 30% of women will die within 1 year after
aving an initial recognized MI. The risk of further cardiac
isease complications, such as another heart attack, sudden
eath, angina pectoris, heart failure and stroke for those
ho survive an MI is substantial (2).
Over the past 30 years, advances in cardiovascular care
ave resulted in a dramatic decline in mortality and mor-
idity associated with STEMI and NSTEMI (3). However,
here is strong evidence that the best treatments and
trategies for these patients are not always pursued. As a
esult, the outcomes of STEMI and NSTEMI patients are
ot as good as they could be with better translation of the
est scientific knowledge to the bedside.
. Writing Committee Structure/Members
he members of the ACC/AHA STEMI/NSTEMI Per-
ormance Measures Writing Committee included senior
linicians, a content expert on STEMI and NSTEMI
erformance measurement, a methodologist, and a statisti-
ian. The Writing Committee also included members of the
merican College of Physicians (ACP), American Acad-
my of Family Physicians (AAFP), and the American
ollege of Emergency Physicians (ACEP).
. Independence/Relationships With Industry Disclosure
he work of the Writing Committee was supported exclu-
ively by the ACC and the AHA. Writing Committee
embers volunteered their time, and there was no commer-
ial support. Meetings of the Writing Committee were
onfidential and attended only by committee members and
taff. All Writing Committee members with relationships
ith industry relevant to this topic declared these in writing
ccording to standard ACC and AHA reporting require-
ents; additionally, members verbally acknowledged these
elationships to the Writing Committee. Please see Appen-
ix C for relevant Writing Committee relationships with
ndustry. In addition, Appendix D includes relevant rela-
ionships with industry information for all peer reviewers of
his document. p. Review/Endorsement
uring the period August 13, 2004 to September 13, 2004,
he ACC/AHA STEMI/NSTEMI Performance Measures
ocument underwent a 30-day public comment period
uring which time ACC and AHA members, as well as
ther health professionals, had an opportunity to review and
omment on the final draft document in advance of its final
pproval and publication. Over 40 responses were received.
The official peer and content review of the document was
onducted simultaneously with the 30-day public comment
eriod, with two peer reviewers nominated by the ACC and
wo reviewers nominated by the AHA. Additional com-
ents were sought from clinical content experts and per-
ormance measurement experts.
The ACC/AHA Clinical Performance Measures for
dults with ST-Elevation and Non–ST-Elevation Myocar-
ial Infarction was adopted by the respective Boards of the
CC and AHA on October, 2005. These measures will be
eviewed for currency annually and will be updated as
eeded. They will be considered valid until they are updated
r rescinded by the ACC/AHA Task Force on Performance
easures.
I. METHODOLOGY
he development of performance systems involves identifi-
ation of a set of measures targeted toward a particular
atient population, observed over a particular time period.
o achieve this goal, the ACC/AHA Task Force on
erformance Measures has outlined and published a meth-
dology of sequential tasks that writing committees are
equired to complete (1). The following sections outline
ow these steps were applied by this Writing Committee.
. Definition of STEMI/NSTEMI
he Writing Committee has incorporated the use of the
erms STEMI and NSTEMI throughout this document
long with the all-inclusive term acute myocardial infarction
AMI) based on the revision of the 1999 ACC/AHA
uideline for the Management of Patients with Acute
yocardial Infarction (4). This guideline update resulted in
he topic of AMI being separated into two guidelines: the
CC/AHA 2002 Guideline Update for the Management
f Patients With Unstable Angina and Non–ST-Segment
levation Myocardial Infarction (5) and the 2004 ACC/
HA Guidelines for the Management of Patients With
T-Elevation Myocardial Infarction (6). The Writing
ommittee has used the term AMI when the measure refers
o both STEMI and NSTEMI patients, while the term
TEMI was used in cases in which the clinical recommen-
ation is specific to STEMI patients only. Measures specific
o NSTEMI patients only are not contained in this set but
ay be considered in future updates.
Specific diagnosis codes, based on ICD-9-CM (Table 1),
hould be used to screen and select the inpatient target
atient population. These codes correspond to the Joint
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ACC/AHA STEMI/NSTEMI Performance Measures January 3, 2006:236–65ommission on Accreditation of Healthcare Organizations
JCAHO) and Centers for Medicare and Medicaid services
CMS) AMI cohort selection codes.
. Dimensions of Care
iven the multiple domains of providing care that can be
easured, the Writing Committee identified and explicitly
rticulated the relevant dimensions of care that should be
valuated. As part of the methodology, each potential
erformance measure was categorized into its relevant
imension of care. Classification into dimensions of care
acilitated identification of areas where evidence was lacking
s well as prevented duplication of measures within the set.
iagnostics, patient education (including prognosis and
tiology), and treatment were selected as the relevant
imensions of care for the STEMI/NSTEMI performance
easures. Self-management and monitoring of disease sta-
us will be evaluated in the future for the inpatient setting.
he committee exclusively focused on processes and did not
onsider outcomes, because the purpose of the measures are
o assist physicians in improving specific clinical care.
. Literature Review
s the primary sources for deriving these measures, this
riting Committee reviewed the 1999 ACC/AHA Guide-
ines for the Management of Patients With Acute Myocar-
ial Infarction (AMI Guideline) (4), the ACC/AHA 2002
uideline Update for Management of Patients with Unsta-
le Angina and Non–ST-Segment Elevation Myocardial
nfarction (UA/NSTEMI guideline) (5), and the 2004
CC/AHA Guidelines for the Management of Patients
ith ST-Elevation Myocardial Infarction (STEMI guide-
ine) (6). The Chair of this Writing Committee also
articipated on the Writing Committee of the latter guide-
able 1. Relevant ICD-9-CM Diagnosis Codes
ICD-9-CM Description
410.01 Anterolateral wall, acute myocardial infarction-initial
episode
410.11 Other anterior wall, acute myocardial infarction-
initial episode
410.21 Inferolateral wall, acute myocardial infarction-initial
episode
410.31 Inferoposterior wall, acute myocardial infarction-
initial episode
410.41 Other inferior wall, acute myocardial infarction-
initial episode
410.51 Other lateral wall, acute myocardial infarction-initial
episode
410.61 True posterior wall, acute myocardial infarction-
initial episode
410.71 Subendocardial, acute myocardial infarction-initial
episode
410.81 Other specified sites, acute myocardial infarction-
initial episode
410.91 Unspecified site, acute myocardial infarction-initial
episodeine. As a participant on the guideline committee, the Chairas able to offer insights into measurement issues and
rovide suggestions for clarity and specificity of guideline
ecommendations. At the same time, the guideline contrib-
ted to the refinement of the measures developed by this
riting Committee.
In addition, existing measure sets, such as those devel-
ped by the JCAHO and CMS, were reviewed by the
riting Committee. See the Discussion section for details
n our efforts to align our measures with CMS and
CAHO.
. Definition and Selection of Measures
xplicit criteria exist for the development of performance
easures so that they can accurately reflect the quality of
are, including quantification of the numerator and denom-
nators of potential measures and evaluating the interpret-
bility, applicability, and feasibility of the proposed measure.
o determine which measures would be considered for
nclusion in the performance measurement set, the Writing
ommittee reviewed and prioritized the class I and class III
ecommendations as potential quality indicators from the
MI guideline, the UA/NSTEMI guideline, and the
TEMI guideline (4–6).
From the analysis of these recommendations, the Writing
ommittee identified potential measures relevant to the
reatment of STEMI and NSTEMI patients. Using the
CC/AHA performance measure rating form and guide
Appendix B), each Writing Committee member rated
otential measures on 13 dimensions using a 5-point Likert
cale (1  lowest rating; 5  highest rating) against the
CC/AHA attributes for good performance measures (Ta-
le 2).
The rating results of the final question on the rating form,
Overall Assessment,” were used to make the final determi-
ation for inclusion of a potential measure in the measure-
ent set. Any measure that received a full committee
able 2. ACC/AHA Attributes for Satisfactory Performance
easures
ACC/AHA Attributes for Satisfactory Performance Measures
Useful in improving patient outcomes
1. Evidence-based
2. Interpretable
3. Actionable
Measure design
1. Denominator precisely defined
2. Numerator precisely defined
3. Validity
a. Face validity
b. Content validity
c. Construct validity
4. Reliability
Measure implementation
1. Feasibility
a. Reasonable effort
b. Reasonable cost
c. Reasonable time period for collectionOverall assessment
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January 3, 2006:236–65 ACC/AHA STEMI/NSTEMI Performance Measuresonsensus rating of 3 or above in this area (“Overall
ssessment”) was advanced for full consideration by the
riting Committee.
In the case of the measure for angiotensin-converting
nzyme inhibitor (ACEI), a Class IIa ACC/AHA
TEMI guidelines recommendation for angiotensin re-
eptor blockers (ARB) was considered and used as the
asis for clarifying the measure constructed by the com-
ittee. Although class IIa recommendations are not
onsidered for stand-alone measures, in some cases (such
s this one) they provide additional information about
alid alternative therapies that are considered by the
ommittee for inclusion in a measure set.
II. STEMI/NSTEMI PERFORMANCE MEASURES
. Inpatient Population and Care Period
he inpatient target population consists of patients aged
8 years or older with a principal discharge diagnosis of
MI (STEMI and NSTEMI) based on ICD-9-CM
Table 1). A set of inclusion and exclusion criteria specific
able 3. ACC/AHA STEMI/NSTEMI Performance Measures:
Performance Measure Name
. Aspirin at Arrival Acute myocardial in
contraindications
. Aspirin Prescribed at Discharge Acute myocardial in
contraindications
. Beta-Blocker at Arrival Acute myocardial in
contraindications
. Beta-Blockers Prescribed at Discharge Acute myocardial in
contraindications
. LDL-Cholesterol Assessment Acute myocardial in
density lipoprotei
LDL-c testing wa
. Lipid-Lowering Therapy at Discharge Acute myocardial in
lipoprotein choles
lowering medicati
. ACEI or ARB for LVSD at Discharge Acute myocardial in
dysfunction (LVS
angiotensin recep
hospital discharge
. Time to Fibrinolytic Therapy Median time from a
elevation or left b
closest to hospital
Acute myocardial in
therapy during th
min or less.
. Time to PCI Median time from a
segment elevation
performed closest
Acute myocardial in
coronary interven
of 90 min or less.
0. Reperfusion Therapy Acute myocardial in
electrocardiogram
primary percutane
1. Adult Smoking Cessation Advice/Counseling Acute myocardial in
cigarettes who are
DL-c  low-density lipoprotein cholesterol; NSTEMI  non–ST-elevation MI; So each inpatient measure was developed. The general ieriod of assessment is the related inpatient hospitaliza-
ion. The specific time period of interest for each measure
s further defined in the full measure specifications
Appendix A).
. Brief Summary of the Measurement Set
able 3 shows the ACC/AHA STEMI/NSTEMI perfor-
ance measurement set—those with the highest level of
vidence and full-consensus support among the committee
embers. The measures include aspirin therapy at arrival
nd discharge, beta-blocker therapy at arrival and discharge,
ow-density lipoprotein cholesterol (LDL-c) assessment,
ipid-lowering therapy at discharge, ACEI, and/or ARB
herapy, time-to-fibrinolytic therapy, time-to-percutaneous
oronary intervention (PCI), reperfusion therapy, and
moking cessation advice/counseling.
Appendix A provides the detailed specifications for
ach inpatient performance measure, including numera-
or, denominator, period of assessment, method of re-
orting, sources of data, rationale, corresponding guide-
ines, secondary measures to consider, and challenges to
tient Measure Descriptions
Measure Description
on (AMI-STEMI and NSTEMI) patients without aspirin
received aspirin within 24 hours before or after hospital arrival.
on (AMI-STEMI and NSTEMI) patients without aspirin
are prescribed aspirin at hospital discharge.
on (AMI-STEMI and NSTEMI) patients without beta-blocker
received a beta-blocker within 24 hours after hospital arrival.
on (AMI-STEMI and NSTEMI) patients without beta-blocker
are prescribed a beta-blocker at hospital discharge.
on (AMI-STEMI and NSTEMI) patients with documentation of low-
lesterol (LDL-c) level in the hospital record or documentation that
e during the hospital stay or is planned for after discharge.
on (AMI-STEMI and NSTEMI) patients with elevated low-density
(LDL-c 100 mg/dl or narrative equivalent) who are prescribed a lipid-
hospital discharge.
on (AMI-STEMI and NSTEMI) patients with left ventricular systolic
d without both angiotensin-converting enzyme inhibitor (ACEI) and
ocker (ARB) contraindications who are prescribed an ACEI or ARB at
to administration of fibrinolytic therapy in patients with ST-segment
branch block (LBBB) on the electrocardiogram (ECG) performed
al time.
on (AMI-STEMI and LBBB only) patients receiving fibrinolytic
pital stay and having a time from hospital arrival to fibrinolysis of 30
to percutaneous coronary intervention (PCI) in patients with ST-
ft bundle branch block (LBBB) on the electrocardiogram (ECG)
rival time.
on (AMI-STEMI and LBBB only) patients receiving percutaneous
PCI) during the hospital stay with a time from hospital arrival to PCI
on (AMI-STEMI only) patients with ST-segment elevation on the
) performed closest to arrival who receive fibrinolytic therapy or
oronary intervention (PCI).
on (AMI-STEMI and NSTEMI) patients with a history of smoking
smoking cessation advice or counseling during hospital stay.
I  ST-elevation MI.Inpa
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ACC/AHA STEMI/NSTEMI Performance Measures January 3, 2006:236–65. Data Collection
o aid in the collection of hospital data, use of a data
ollection tool or flow sheet is recommended. The flow
heet may be developed at individual institutions to conform
o local workflow issues and data collection practices.
xamples of useful data collection tools are available from
CC’s Guideline Applied in Practice (GAP) program Web
ite (http://www.acc.org/gap/mi/ami_downloadA.htm) and
he AHA’s Get With The Guidelines (GWTG) program web
ite (http://www.americanheart.org/presenter.jhtml?identi-
er3003994 ). The tools can be modified for implementation
t your institution in order to be used in practice.
To further the use of standardized terminology and data
efinitions in the field of cardiology, those collecting data on
atients with STEMI or NSTEMI are referred to the ACC
ey Data Elements and Definitions for Measuring the
linical Management and Outcomes of Patients with Acute
oronary Syndromes (7).
V. DISCUSSION
he ACC/AHA Clinical Performance Measures for Adults
ith ST-Elevation and Non–ST-Elevation MI addresses
any of the same processes of care as earlier measurement
ets published by other organizations. These measures were
eveloped by employing the ACC/AHA methodology for
eveloping performance measure sets (3). The Writing
ommittee has been cognizant of the previous efforts of
ther groups and sought to enhance and clarify measures in
ays that reflect the advancement of the underlying science,
he complexity of care, and the challenges of accurate and
omplete data collection. As such, the Writing Committee
as made every attempt to align these measures with those
able 4. ACC/AHA STEMI/NSTEMI Performance Measurem
Performance Measure Diagnostics
Patient
Education
. Aspirin at Arrival
. Aspirin Prescribed at
Discharge
. Beta-Blocker at Arrival
. Beta-Blockers Prescribed
at Discharge
. LDL-Cholesterol
Assessment
✓
. Lipid-Lowering Therapy
at Discharge
. ACEI or ARB for LVSD
. Time to Fibrinolytic
Therapy
. Time to PCI
0. Reperfusion Therapy
1. Adult Smoking Cessation ✓
Advice/Counseling
Although no current measures exist for these dimensions of care for the inpatient
easurement set.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptorromulgated by CMS and JCAHO. iThis Writing Committee felt it was important to add
xclusion criteria to the measures to recognize that there are
ustifiable medical and patient reasons for not meeting the
erformance measures. These reasons should be included in
he “reasons documented by physician, nurse practitioner, or
ther health care provider for not. . .” Documentation of
uch factors should be encouraged and will provide valuable
ata for future research and conducting in-depth QI for
ituations where there seem to be outliers with respect to the
umber of patients with medical or patient-centered exclu-
ions for the performance measures.
Challenges to implementation of measures are discussed,
here applicable. In general, inadequate documentation is
he initial challenge of any measurement effort. The fact
hat these challenges are discussed is not intended as an
rgument against measurement. Rather, they should be
onsidered as cautionary notes that draw attention to areas
here additional focus on research and improvement of the
easures should be considered.
Four areas in this measurement set warrant further
iscussion: the addition of ARBs to the ACEI for left
entricular systolic dysfunction (LVSD) measure (#7),
he use of “median” versus “mean” in the time-to-
brinolytic measure (#8), the new standard for the
ime-to-PCI measure (#9), and the new reperfusion
herapy (#10) measure.
. Addition of ARBs to ACEI Measure
he measurement set includes ARBs along with ACEI
rescription on discharge. Although Class IIa recom-
endations are not considered for stand-alone measures,
n this case, the additional information provided about
alid alternative therapies allowed it to be considered for
et: Dimensions of Care Inpatient Measures Matrix
Treatment Self-Management
Monitoring of Disease
Status*
✓
✓
✓
✓
✓
✓
✓
✓
✓
g, future measure development efforts will examine how to address this gap in the
r; LDL  low-density lipoprotein; LVSD  left ventricular systolic dysfunction.ent S
settinnclusion in the measure. This change is made with
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January 3, 2006:236–65 ACC/AHA STEMI/NSTEMI Performance Measuresecognition that although the guidelines still recommend
CEI as first-line therapy, physicians should be given
redit for prescribing or continuing ARB therapy. The
upport for the use of ARBs has evolved significantly in
esponse to published clinical trials that have shown
RBs as an effective alternative therapy and is recom-
ended in the 2004 ACC/AHA STEMI guidelines (6)
s a reasonable alternative therapy.
. Median—Time-to-Fibrinolytic Therapy and
ime-to-Primary PCI Measures
edian better represents the typical time achieved than
oes mean. The mean time can be unduly skewed by outlier
imes, even as there are upper limits on the time. Thus, the
ommittee favored reporting the median time. This is a
ontrast with the corresponding CMS/JCAHO measure,
hich reports the values in mean time. The CMS/JCAHO
quivalent measures will report the median for discharges
ffective January 1, 2006. The information was released to
he community in late August 2005.
. New Standard for Time-to-Primary PCI Measure
his measurement set establishes the time-to-PCI standard
t 90 min, which is different than the 120-min standard
sed in the current CMS and JCAHO measures. This
hange reflects the new recommendation from the 2004
CC/AHA STEMI guidelines that, “delay from patient
ontact with the health care system (typically, arrival at the
mergency department or contact with paramedics) to
alloon inflation should be less than 90 min” (6). p. New Reperfusion Therapy Measure
he new reperfusion therapy measure is meant to capture
he percentage of patients eligible for reperfusion (either
brinolytic therapy or PCI) who are reperfused. This
easure is meant to assist facilities in assessing the appro-
riateness of their use of reperfusion therapy and detecting
nderutilization of reperfusion.
Although the Writing Committee considered a number of
dditional potential measures that focus on equally important
spects of care, either the evidence base or more significant
hallenges to measurement of these components of care across
ll patients undermined the benefits that might be gained. Of
ote, the committee discussed at length the possibility of
ncluding a clopidogrel measure and a measure for ACEI in
atients with left ventricular ejection fraction (LVEF) greater
han 0.40, but it felt that the evidence-base did not yet support
heir inclusion as a performance measure. The Writing Com-
ittee will monitor changes in the evidence in new clinical
rials and will determine whether additional measures should
e added in the future.
The ACC/AHA STEMI/NSTEMI performance mea-
urement set should contribute to the evolution of reporting
ystems that allow physicians to improve care for a critical
atient population. QI is a continuous process, and this
ocument reflects the lessons the practicing community has
earned to date in using existing measures and knowledge
ained about how they might be improved. The clinical care
eam should collect data and review adherence to these
easures on a routine basis, look for changes, and adjustractice patterns as necessary to improve performance.
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ACC/AHA STEMI/NSTEMI Performance Measures January 3, 2006:236–65PPENDIX A. ACC/AHA STEMI/NSTEMI Measurement Set Specifications
1. Aspirin at Arrival
Acute myocardial infarction (AMI–STEMI and NSTEMI) patients without aspirin contraindications
who received aspirin within 24 hours before or after hospital arrival.
umerator AMI patients who received aspirin within 24 hours before or after hospital arrival.
enominator AMI patients without aspirin contraindications.
Included populations: Discharges with an ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2.
Excluded populations:
● Patients less than 18 years of age
● Patients transferred to another acute care hospital or federal hospital on day of or day after arrival
● Patients received in transfer from another acute care hospital, including another emergency department
● Patients discharged on day of arrival
● Patients who expired on day of or day after arrival
● Patients who left against medical advice on day of or day after arrival
● Patients with one or more of the following aspirin contraindications/reasons for not prescribing aspirin documented in the
medical record:
- Active bleeding on arrival or within 24 hours after arrival
- Aspirin allergy
- Coumadin/warfarin as pre-arrival medication
- Other reasons documented by physician, nurse practitioner, or physician assistant for not giving aspirin within 24 hours
before or after hospital arrival*
eriod of assessment Within 24 hours before or after hospital arrival.
ources of data Administrative data and medical records.
Rationale
he use of aspirin has been shown to reduce mortality with AMI.
Corresponding Guideline(s)
CC/AHA STEMI Guidelines (6)
lass I
spirin should be chewed by patients who have not taken aspirin before presentation with STEMI. The initial dose should be 162 mg (Level of Evidence:
) to 325 mg (Level of Evidence: C). Although some trials have used enteric-coated aspirin for initial dosing, more rapid buccal absorption occurs with
on–enteric-coated aspirin formulations.
CC/AHA UA/NSTEMI Guidelines (5)
lass I
ntiplatelet therapy should be initiated promptly. Aspirin should be administered as soon as possible after presentation and continued indefinitely (Level
f Evidence: A).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
This also includes aspirin intolerance.
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January 3, 2006:236–65 ACC/AHA STEMI/NSTEMI Performance Measures2. Aspirin Prescribed at Discharge
Acute myocardial infarction (AMI–STEMI and NSTEMI) patients without aspirin contraindications
who are prescribed aspirin at hospital discharge
umerator AMI patients who are prescribed aspirin at hospital discharge.
enominator AMI patients without aspirin contraindications.
Included populations: Discharges with an ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2.
Excluded populations:
● Patients less than 18 years of age
● Patients transferred to another acute care hospital or federal hospital
● Patients who expired
● Patients who left against medical advice
● Patients discharged to hospice
● Patients with one or more of the following aspirin contraindications/reasons for not prescribing aspirin documented in the
medical record:
- Aspirin allergy
- Active bleeding on arrival or during hospital stay
- Coumadin/warfarin prescribed at discharge
- Other reasons documented by physician, nurse practitioner, or physician assistant for not prescribing aspirin at
discharge*
eriod of assessment Hospital discharge.
ources of data Administrative data and medical records.
Rationale
he use of aspirin has been shown to reduce recurrent MI and death in patients surviving an initial MI.
Corresponding Guideline(s)
CC/AHA STEMI Guidelines (6)
lass I
daily dose of aspirin (initial dose of 162 to 325 mg orally; maintenance dose of 75 to 162 mg) should be given indefinitely after STEMI to all patients
ithout a true aspirin allergy (Level of Evidence: A).
CC/AHA UA/NSTEMI Guidelines (5)
lass I
ntiplatelet therapy should be initiated promptly. Aspirin should be administered as soon as possible after presentation and continued indefinitely (Level
f Evidence: A).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
This also includes aspirin intolerance.
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ACC/AHA STEMI/NSTEMI Performance Measures January 3, 2006:236–653. Beta-Blocker at Arrival
Acute myocardial infarction (AMI–STEMI and NSTEMI) patients without beta-blocker contraindications
who received a beta-blocker within 24 hours after hospital arrival
umerator AMI patients who received a beta-blocker within 24 hours after hospital arrival.
enominator AMI patients without beta blocker contraindications.
Included populations: Discharges with an ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2.
Excluded populations:
● Patients less than 18 years of age
● Patients transferred to another acute care hospital or federal hospital on day of or day after arrival
● Patients received in transfer from another acute care hospital, including another emergency department.
● Patients discharged on day of arrival
● Patients who expired on day of or day after arrival
● Patients who left against medical advice on day of or day after arrival
● Patients with one or more of the following beta-blocker contraindications/reasons for not prescribing beta-blocker
documented in the medical record:
- Beta-blocker allergy
- Bradycardia (heart rate less than 60 beats/min) on arrival or within 24 hours after arrival while not on a beta-blocker
- Heart failure on arrival or within 24 hours after arrival
- Second- or third-degree heart block on ECG on arrival or within 24 hours after arrival and does not have a pacemaker
- Shock on arrival or within 24 hours after arrival
- Other reasons documented by a physician, nurse practitioner, or physician assistant for not giving a beta-blocker within
24 hours after hospital arrival*
eriod of assessment Within 24 hours after hospital arrival.
ources of data Administrative data and medical records.
Rationale
o reduce ventricular arrhythmias, recurrent ischemia, reinfarction, and if given early enough, infarct size and short-term mortality.
Corresponding Guideline(s)
CC/AHA STEMI Guidelines (6)
lass I
ral beta-blocker therapy should be administered promptly to those patients without a contraindication, irrespective of concomitant fibrinolytic therapy or
erformance of primary PCI (Level of Evidence: A).
CC/AHA UA/NSTEMI Guidelines (5)
lass I
beta-blocker, with the first dose administered intravenously if there is ongoing chest pain, followed by oral administration, in the absence of
ontraindications (Level of Evidence: B).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
This also includes beta-blocker intolerance.
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January 3, 2006:236–65 ACC/AHA STEMI/NSTEMI Performance Measures4. Beta-Blocker Prescribed at Discharge
Acute myocardial infarction (AMI–STEMI and NSTEMI) patients without beta-blocker contraindications
who are prescribed a beta-blocker at hospital discharge
umerator AMI patients who are prescribed a beta-blocker at hospital discharge.
enominator AMI patients without beta-blocker contraindications.
Included populations: Discharges with an ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2.
Excluded populations:
● Patients less than 18 years of age
● Patients transferred to another acute care hospital or federal hospital
● Patients who expired
● Patients who left against medical advice
● Patients discharged to hospice
● Patients with one or more of the following beta-blocker contraindications/reasons for not prescribing a beta-blocker
documented in the medical record:
- Beta-blocker allergy
- Bradycardia (heart rate less than 60 beats/min) on day of discharge or day prior to discharge while not on a beta-
blocker
- Second- or third-degree heart block on ECG on arrival or during hospital stay and does not have a pacemaker
- Other reasons documented by a physician, nurse practitioner, or physician assistant for not prescribing a beta-blocker at
discharge*
eriod of assessment Hospital discharge.
ource of data Administrative data and medical records.
Rationale
eduction in recurring events and long-term mortality.
Corresponding Guideline(s)
CC/AHA STEMI Guidelines (6)
lass I
ll patients after STEMI except those at low risk (normal or near-normal ventricular function, successful reperfusion, absence of significant ventricular
rrhythmias) and those with contraindications should receive beta-blocker therapy. Treatment should begin within a few days of the event, if not initiated
cutely, and continue indefinitely (Level of Evidence: A).
lass IIa
t is reasonable to prescribe beta-blockers to low-risk patients after STEMI who have no contraindications to that class of medications (Level of Evidence: A).
CC/AHA UA/NSTEMI Guidelines (5)
lass I
eta-blockers in the absence of contraindications (Level of Evidence: A).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
This also includes beta-blocker intolerance.
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ACC/AHA STEMI/NSTEMI Performance Measures January 3, 2006:236–655. LDL-Cholesterol Assessment
Acute myocardial infarction (AMI–STEMI and NSTEMI) patients with documentation of low-density lipoprotein-cholesterol (LDL-c) level in
the hospital record or documentation that LDL-c testing was done during the hospital stay or is planned for after discharge
umerator AMI patients with documentation of LDL-c level in the hospital record or documentation that LDL-c testing was done
either during the hospital stay or is planned for after discharge.
enominator AMI patients.
Included populations: Discharges with an ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2.
Excluded populations:
● Patients less than 18 years of age
● Patients transferred to another acute care hospital or federal hospital
● Patients who expired
● Patients who left against medical advice
● Patients discharged to hospice
● Lipid-lowering medication are pre-arrival medication
● Patients with reason documented by a physician, nurse practitioner, or physician assistant for no LDL-c testing
eriod of assessment Inpatient admission.
ource of data Administrative data and medical records.
Rationale
easurement of lipid levels in patients with STEMI and NSTEMI is essential to gauging the need for lipid-lowering therapy and/or dietary modification
nd assessing the risk of subsequent coronary events.
Corresponding Guideline(s)
HA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update (8)
ssess fasting lipid profile in all patients, and within 24 hours of hospitalization for those with an acute event.
CC/AHA STEMI Guidelines (6)
lass I
lipid profile should be performed, or obtained from recent or past records, for all STEMI patients, preferably after they have fasted and within 24 hours
f symptom onset (Level of Evidence: C).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
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January 3, 2006:236–65 ACC/AHA STEMI/NSTEMI Performance Measures6. Lipid-Lowering Therapy at Discharge
Acute myocardial infarction (AMI–STEMI and NSTEMI) patients with elevated low-density lipoprotein-cholesterol (LDL-c >100 mg/dl or
narrative equivalent) who are prescribed a lipid-lowering medication at hospital discharge.
umerator AMI patients who are prescribed lipid-lowering medication at hospital discharge.
enominator AMI patients with elevated LDL-c.
Included populations: Discharges with:
● An ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2 AND
● Patients with one or more of the following documented in the medical record:
- LDL-c 100 mg/dl (or narrative equivalent) on test performed during hospital stay OR
- If no in-hospital test result, LDL-c 100 mg/dl (or narrative equivalent) on test performed prior to arrival
Excluded populations:
● Patients less than 18 years of age
● Patients transferred to another acute care hospital or federal hospital
● Patients who expired
● Patients who left against medical advice
● Patients discharged to hospice
● Patients who did not receive lipid-lowering medication and had a reason documented by a physician, nurse practitioner, or
physician assistant for not prescribing lipid-lowering medication at discharge*
eriod of assessment Hospital discharge.
ources of data Administrative data and medical records.
Rationale
ultiple clinical trials have shown the benefit of lipid-lowering therapy for patients who have had an acute coronary event. Initiation of lipid-lowering
herapy at discharge is preferred to enhance patient compliance with medication therapy.
Corresponding Guideline(s)
CC/AHA UA/NSTEMI Guidelines (5)
lass I
ipid-lowering agents and diet in post-acute coronary syndrome patients, including post-revascularization patients, with LDL-c greater than 130 mg/dl
Level of Evidence: A).
ipid-lowering agents if LDL-c level after diet is greater than 100 mg/dl (Level of Evidence: B).
CC/AHA STEMI Guidelines (6)
lass I
he target LDL-c level after STEMI should be substantially less than 100 mg/dl. Patients with LDL-c 100 mg/dl or above should be prescribed drug
herapy on discharge, with preference given to statins (Level of Evidence: A).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
This also includes intolerance to lipid-lowering medication.
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ACC/AHA STEMI/NSTEMI Performance Measures January 3, 2006:236–657. ACEI or ARB for LVSD at Discharge
Acute myocardial infarction (AMI–STEMI and NSTEMI) patients with left ventricular systolic dysfunction (LVSD) and without both
angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) contraindications
who are prescribed an ACEI or ARB at hospital discharge.
(For purposes of this measure, LVSD is defined as chart documentation of a left ventricular ejection fraction [LVEF] less than 40% or a
narrative description of left ventricular systolic [LVS] function consistent with moderate or severe systolic dysfunction.)
umerator AMI patients who are prescribed an ACEI or ARB at hospital discharge.
enominator AMI patients with LVSD and without both ACEI and ARB contraindications.
Included populations: Discharges with:
● An ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2 AND
● Chart documentation of a LVEF less than 40% or a narrative description of LVS function consistent with moderate or
severe systolic dysfunction.
Excluded populations:
● Patients less than 18 years of age
● Patients transferred to another acute care hospital or federal hospital
● Patients who expired
● Patients who left against medical advice
● Patients discharged to hospice
● Patients with BOTH a potential contraindication/reason for not prescribing an ACEI at discharge AND a potential
contraindication/reason for not prescribing an ARB at discharge, as evidenced by one or more of the following:
- ACEI or ARB allergy
- Moderate or severe aortic stenosis
- Physician, nurse practitioner, or physician assistant documentation of BOTH a reason for not prescribing an ACEI at
discharge AND a reason for not prescribing an ARB at discharge*
- Reason documented by physician, nurse practitioner, or physician assistant for not prescribing an ARB at discharge
AND an ACEI allergy
- Reason documented by physician, nurse practitioner, or physician assistant for not prescribing an ACEI at discharge
AND an ARB allergy.*
eriod of assessment Hospital discharge.
ources of data Administrative data and medical records.
Rationale
CEIs have been shown to reduce mortality rates for patients with AMI (or who recently had an MI) and have LVSD (9–13). Benefit has been greatest
or those with anterior MI and those with greater LV dysfunction (LVEF 0.40). Benefit also has been shown in diabetic patients with LV dysfunction
14). Current guidelines (5,6) recommend (Class I designation) in-hospital initiation (within 24 hours) and outpatient continuation indefinitely.
The use of ARBs post-STEMI has not been as thoroughly explored as ACEIs in STEMI patients. The OPTIMAAL trial found no significant
ifferences between losartan (target dose 50 mg once daily) and captopril (target dose 50 mg three times daily) in all-cause mortality (15); there was a trend
oward better outcome with captopril. The VALIANT trial compared the effects of captopril (target dose 50 mg three times daily), valsartan (target dose
60 mg twice daily), and the combination (captopril target dose 50 mg three times daily; valsartan target dose 80 mg twice daily) on mortality in post-MI
atients with LV dysfunction (16). During a median follow-up of 24.7 months, death occurred in 19.9% of the valsartan group, 19.5% of the captopril
roup, and 19.3% of the combined group. Accordingly, guidelines suggest that valsartan monotherapy (target dose 160 mg twice daily) should be
dministered to STEMI patients who are intolerant of ACEIs and have evidence of LV dysfunction. However, guidelines also state that valsartan
onotherapy can be a useful alternative to ACEIs—the decision in individual patients may be influenced by physician and patient preference, cost, and
nticipated side-effect profile (6).
Corresponding Guideline(s)
CC/AHA STEMI Guidelines (6)
lass I
n ACEI should be administered orally within the first 24 hours of STEMI to patients with an anterior MI, pulmonary congestion, or LVEF less than
.40, in the absence of hypotension (systolic blood pressure less than 100 mm Hg or less than 30 mm Hg below baseline) or known contraindications to
hat class of medications (Level of Evidence: A).
n ARB should be administered to STEMI patients who are intolerant of ACEIs and who have either clinical or radiological signs of heart failure or LVEF
ess than 0.40. Valsartan and candesartan have established efficacy for this recommendation (Level of Evidence: C).
n ACEI should be administered orally during convalescence from STEMI in patients who tolerate this class of medication, and it should be continued
ver the long term (Level of Evidence: A).
n ARB should be administered to STEMI patients who are intolerant of ACEIs and have either clinical or radiological signs of heart failure or LVEF
ess than 0.40. Valsartan and candesartan have demonstrated efficacy for this recommendation (Level of Evidence: B).
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January 3, 2006:236–65 ACC/AHA STEMI/NSTEMI Performance Measureslass IIa
n STEMI patients who tolerate ACEIs, an ARB can be useful as an alternative to ACEIs provided there are either clinical or radiological signs of heart
ailure or LVEF is less than 0.40. Valsartan and candesartan have established efficacy for this recommendation (Level of Evidence: B).
CC/AHA UA/NSTEMI Guidelines (5)
lass I
ong-Term Medical Therapy
CEIs for patients with CHF, LV dysfunction (LVEF less than 0.40), hypertension, or diabetes (Level of Evidence: A).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
Challenges to Implementation
etermination of who has LVEF 0.40 is a potential challenge to implementation as well as how this can be reasonably, consistently, and reliably located
n the patient record. Also, future updates may consider whether the determination of ACEI or ARB use is made only at discharge (discharge medication
ist) or whether additional credit should be provided for inhospital initiation and titration. Quality improvement efforts also should consider whether
rescription of only specific agents or specific dose-ranges (based on clinical trial evidence) should be encouraged.
This also includes ACEI or ARB intolerance.
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ACC/AHA STEMI/NSTEMI Performance Measures January 3, 2006:236–658. Time to Fibrinolytic Therapy
Median time from arrival to administration of fibrinolytic agent in patients with ST-segment elevation or left bundle branch block (LBBB) on
the electrocardiogram (ECG) performed closest to hospital arrival time.
Acute myocardial infarction (AMI–STEMI and LBBB only) patients receiving fibrinolytic therapy during the hospital stay and having a time
from hospital arrival to fibrinolysis of 30 min or less.
umerator AMI patients whose time from hospital arrival to fibrinolytic therapy is 30 min or less.
enominator AMI patients with ST-elevation or LBBB on ECG who received fibrinolytic therapy.
Included populations: Discharges with:
● An ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2 AND
● ST-segment elevation or LBBB on the ECG performed closest to hospital arrival AND
● Fibrinolytic therapy within 6 hours after hospital arrival AND
● Fibrinolytic therapy is primary reperfusion therapy
Excluded populations:
● Patients less than 18 years of age
● Patients received in transfer from another acute care hospital including another emergency department
● Other reasons documented by physician, nurse practitioner, or physician assistant for delay in fibrinolytic therapy (e.g.,
social, religious, initial concern or refusal)
eriod of assessment Within 6 hours after hospital arrival.
ources of data Administrative data and medical records.
Rationale
here are a multitude of experimental and clinical studies that demonstrate that amount of myocardial salvage is directly related to time of fibrinolytic
herapy administration. The earlier the treatment, the more myocardium is salvaged (i.e., “time is muscle”). Total time to fibrinolytic drug administration
s dependent on a multitude of processes that begins on patient’s arrival to the emergency department. The National Heart Attack Alert Program has chosen
o focus on four D’s of the overall process: Door, Data, Decision, and Delivery. The three easiest data points to measure on retrospective chart review are
oor (arrival time), Data (ECG time), and Delivery (time of drug administration). Decision time can only be determined if the physician documents in
he medical records the actual time that he/she gave the order for fibrinolytic drug administration. Data time only truly reflects actual data time if physician
mmediately reviews ECG results (“data not seen is data not done”).
Corresponding Guideline(s)
oor-to-Data (ECG) Time
CC/AHA STEMI Guidelines (6)
lass I
12-lead ECG should be performed and shown to an experienced emergency physician within 10 min of emergency department arrival for all patients
ith chest discomfort (or anginal equivalent) or other symptoms suggestive of STEMI (Level of Evidence: C).
CC/AHA UA/NSTEMI Guidelines (5)
lass I
12-lead ECG should be obtained immediately (within 10 min) in patients with ongoing chest discomfort and as rapidly as possible in patients who have
history of chest discomfort consistent with acute coronary syndrome but whose discomfort has resolved by the time of evaluation (Level of Evidence: C).
ata-to-Decision Time
o ACC/AHA Guideline Recommendations
ecision-to-Delivery Time
o ACC/AHA Guideline Recommendations
oor-to-Delivery (fibrinolytic drug administration) Time
CC/AHA STEMI Guidelines (6)
lass I
he delay from patient contact with the health care system (arrival at the emergency department or contact with paramedics) to initiation of fibrinolytic
herapy should be less than 30 min. Alternatively, if PCI is chosen, the delay from patient contact with the health care system (typically, arrival at the
mergency department or contact with paramedics) to balloon inflation should be less than 90 min (Level of Evidence: B).
CC/AHA Indications for Fibrinolytic Therapy–ST-Segment Elevation Cohort
CC/AHA STEMI Guidelines (6)
lass I
ll STEMI patients should undergo rapid evaluation for reperfusion therapy and have a reperfusion strategy implemented promptly after contact with the
edical system (Level of Evidence: A).
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January 3, 2006:236–65 ACC/AHA STEMI/NSTEMI Performance MeasuresCC/AHA UA/NSTEMI Guidelines (5)
lass I
atients with definite acute coronary syndrome and ST-segment elevation should be evaluated for immediate reperfusion therapy (Level of Evidence: A).
CC/AHA Indications for Fibrinolytic Therapy–LBBB Cohort
CC/AHA STEMI Guidelines (6)
lass I
n the absence of contraindications, fibrinolytic therapy should be administered to STEMI patients with symptom onset within the prior 12 hours and new
r presumably new LBBB (Level of Evidence: A).
Method of Reporting
ime: Aggregate measure of central tendency (median as calculated based on patients in the denominator within the period of assessment).
er patient population: Aggregate rate (standard error) generated from count data reported as a proportion.
Secondary Measures to Consider
Door-to-ECG
ECG-to-decision
Decision-to-fibrinolytic drug administration
Challenges to Implementation
o major challenges are anticipated for overall time to fibrinolytic therapy, as a version of this measure is among the core measures that CMS and JCAHO
equire and is one of the major measures in the NRMI dataset (as well as time to ECG). Also ECG time is easily measured but may not reflect actual time
f processes are not in place to ensure immediate physician interpretation. The major challenge would be to implement a measure of the decision time, as
his would require a strong presence of emergency department directors in insisting upon better documentation.
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Median time from arrival to percutaneous coronary intervention (PCI) in patients with ST-segment elevation or left bundle branch block
(LBBB) on the electrocardiogram (ECG) performed closest to arrival time.
Acute myocardial infarction (AMI–STEMI and LBBB only) patients receiving PCI during the hospital stay with a time from
hospital arrival to PCI of 90 min or less.
umerator AMI patients whose time from hospital arrival to PCI is 90 min or less.
enominator AMI patients with ST-segment elevation or LBBB on ECG who received PCI.
Included populations: Discharges with:
● An ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2 AND
● PCI (ICD-9-CM Principal or Other Procedure Codes for PCI) AND
● ST-segment elevation or LBBB on the ECG performed closest to hospital arrival AND
● PCI performed within 24 hours after hospital arrival
Excluded populations:
● Patients less than 18 years of age
● Patients received in transfer from another acute care hospital including another emergency department
● Patients administered fibrinolytic agent prior to PCI
● MD/NP/PA described the PCI as non-primary
● Other reasons documented by physician, nurse practitioner, or physician assistant for delay in PCI (e.g., social, religious,
initial concern or refusal)
eriod of assessment Within 24 hours after hospital arrival.
ources of data Administrative data and medical records.
Rationale
he role of primary angioplasty in STEMI patients presenting to the emergency department with contraindications to fibrinolytic therapy is clear. Likewise,
t is well-established that emergency PCI is more effective than fibrinolytic therapy in centers in which PCI can be performed by experienced personnel
n a timely fashion. What is debatable is the utility of primary angioplasty in the typical community hospital. Since fibrinolytic therapy can be administered
n most centers within 30 to 60 min of arrival, and since fibrinolytic therapy usually opens the occluded artery within 60 to 90 min, this equates to reperfused
rtery in 90 to 150 min after emergency department arrival in patients with STEMI treated with fibrinolytic therapy. Since “time is muscle,” there obviously
as to be a time from arrival until balloon insufflation in which the benefits of PCI are lost due to excess myocardial death that would have been spared
ad fibrinolytic therapy been administered. Thus, it is imperative to continually strive to improve door-to-balloon times such that the benefits of PCI are
ot lost from the excess cell death due to delays in opening occluded vessel.
Corresponding Guideline(s)
oor-to-Data (ECG) Time
CC/AHA STEMI Guidelines (6)
lass I
12-lead ECG should be performed and shown to an experienced emergency physician within 10 min of emergency department arrival for all patients
ith chest discomfort (or anginal equivalent) or other symptoms suggestive of STEMI (Level of Evidence: C).
CC/AHA UA/NSTEMI Guidelines (5)
lass I
12-lead ECG should be obtained immediately (within 10 min) in patients with ongoing chest discomfort and as rapidly as possible in patients who have
history of chest discomfort consistent with acute coronary syndrome but whose discomfort has resolved by the time of evaluation (Level of Evidence: C).
ata-to-Decision Time
o ACC/AHA Guideline Recommendations
ecision-to-Delivery Time
o ACC/AHA Guideline Recommendations
oor-to-Delivery Time (primary PCI)
CC/AHA STEMI Guidelines (6)
lass I
he delay from patient contact with the health care system (arrival at the emergency department or contact with paramedics) to initiation of fibrinolytic
herapy should be less than 30 min. Alternatively, if PCI is chosen, the delay from patient contact with the health care system (typically, arrival at the
mergency department or contact with paramedics) to balloon inflation should be less than 90 min (Level of Evidence: B).
CC/AHA Indications for Primary PCI
CC/AHA STEMI Guidelines (6)
lass I
ll STEMI patients should undergo rapid evaluation for reperfusion therapy and have a reperfusion strategy implemented promptly after contact with the
edical system (Level of Evidence: A).
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January 3, 2006:236–65 ACC/AHA STEMI/NSTEMI Performance Measureshe delay from patient contact with the health care system (arrival at the emergency department or contact with paramedics) to initiation of fibrinolytic
herapy should be less than 30 min. Alternatively, if PCI is chosen, the delay from patient contact with the health care system (typically, arrival at the
mergency department or contact with paramedics) to balloon inflation should be less than 90 min (Level of Evidence: B).
CC/AHA UA/NSTEMI Guidelines (5)
lass I
atients with definite acute coronary syndrome and ST-segment elevation should be evaluated for immediate reperfusion therapy (Level of Evidence: A).
BBB Cohort
CC/AHA STEMI Guidelines (6)
lass I
f immediately available, primary PCI should be performed in patients with STEMI (including true posterior MI) or MI with new or presumably new
BBB who can undergo PCI of the infarct artery within 12 hours of symptom onset, if performed in a timely fashion (balloon inflation within 90 min of
resentation) by persons skilled in the procedure (individuals who perform more than 75 PCI procedures per year). The procedure should be supported by
xperienced personnel in an appropriate laboratory environment (performs more than 200 PCI procedures per year, of which at least 36 are primary PCI
or STEMI, and has cardiac surgery capability) (Level of Evidence: A).
Method of Reporting
ime: Aggregate measure of central tendency (median as calculated based on patients in the denominator within the period of assessment).
er patient population: Aggregate rate (standard error) generated from count data reported as a proportion.
Secondary Measures to Consider
Door-to-ECG
ECG-to-decision
Decision-to-cath lab arrival
Cath lab arrival-to-balloon time
Challenges to Implementation
o major challenges are anticipated as a version of this measure is already a core measure of CMS and JCAHO and is one of the major measures in the
RMI dataset. The biggest difficulty in measuring the time period is typically due to poor documentation in the cath lab. Measurement efforts must also
e specific and consistent in defining the time of angioplasty (assumed to be time of first balloon insufflation).
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Acute myocardial infarction (AMI–STEMI only) patients with ST-segment elevation on the electrocardiogram (ECG)
performed closest to arrival, who receive fibrinolytic therapy or primary percutaneous coronary intervention (PCI)
umerator AMI patients who receive fibrinolytic therapy or primary PCI.
enominator AMI patients with ST-segment elevation on ECG who received fibrinolytic therapy or primary PCI.
Included populations: Discharges with:
● An ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2 AND
● ST-segment elevation on the ECG performed closest to hospital arrival AND
● Patients presenting within 12 hours of symptom onset.
Excluded populations:
● Patients less than 18 years of age
● Patient refusal of reperfusion therapy
● Other reasons documented by a physician, nurse practitioner, or physician assistant for not doing reperfusion therapy
eriod of assessment Within 12 hours of symptom onset.
ources of data Administrative data and medical records.
Rationale
vidence exists that expeditious restoration of flow in the obstructed infarct artery after the onset of symptoms in STEMI patients is a key determinant
f short- and long-term outcomes regardless of whether reperfusion is accomplished by fibrinolysis or PCI. Despite such strong evidence, studies continue
o indicate that reperfusion therapy is underutilized and often not administered soon after presentation. Indecision about the choice of reperfusion therapy
hould not deter physicians from using these strategies or delay them in administering therapy.
Corresponding Guideline(s)
CC/AHA Indications for Fibrinolytic Therapy–ST-Segment Elevation Cohort
CC/AHA STEMI Guidelines (6)
lass I
ll STEMI patients should undergo rapid evaluation for reperfusion therapy and have a reperfusion strategy implemented promptly after contact with the
edical system (Level of Evidence: A).
CC/AHA UA/NSTEMI Guidelines (5)
lass I
atients with definite acute coronary syndrome and ST-segment elevation should be evaluated for immediate reperfusion therapy (Level of Evidence: A).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
ND
P
S
I
r
n
A
C
P
s
a
P
C
s
A
C
S
o
C
E
A
257JACC Vol. 47, No. 1, 2006 Krumholz et al.
January 3, 2006:236–65 ACC/AHA STEMI/NSTEMI Performance Measures11. Adult Smoking Cessation Advice/Counseling
Acute myocardial infarction (AMI–STEMI and NSTEMI) patients with a history of smoking cigarettes,
who are given smoking cessation advice or counseling during hospital stay.
(For the purposes of this measure, a smoker is defined as someone who has smoked cigarettes anytime during the year prior to hospital arrival.)
umerator AMI patients (cigarette smokers) who receive smoking cessation advice or counseling during the hospital stay
enominator AMI patients with a history of smoking cigarettes anytime during the year prior to hospital arrival.
Included population: Discharges with:
● An ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2 AND
● A history of smoking cigarettes anytime during the year prior to hospital arrival.
Excluded populations:
● Patients less than 18 years of age
● Patients transferred to another acute care hospital or federal hospital
● Patients who expired
● Patients who left against medical advice
● Patients discharged to hospice
eriod of assessment Hospital discharge.
ources of data Administrative data and medical records.
Rationale
n patients who have undergone an acute coronary event, smoking cessation is essential to their recovery, long-term health, and the prevention of subsequent
einfarction. All STEMI and NSTEMI patients with a history of smoking should be advised to quit and offered smoking cessation resources including
icotine replacement therapy, pharmacological therapy (i.e., bupropion), and referral to behavioral counseling or support group.
Corresponding Guideline(s)
CC/AHA STEMI Guidelines (6)
lass I
atient counseling to maximize adherence to evidence-based post-STEMI treatments (e.g., compliance with taking medication, exercise prescription, and
moking cessation) should begin during the early phase of hospitalization, occur intensively at discharge, and continue at follow-up visits with providers
nd through cardiac rehabilitation programs and community support groups, as appropriate (Level of Evidence: C).
atients recovering from STEMI who have a history of cigarette smoking should be strongly encouraged to stop smoking and to avoid secondhand smoke.
ounseling should be provided to the patient and family, along with pharmacological therapy (including nicotine replacement and bupropion) and formal
moking cessation programs as appropriate (Level of Evidence: B).
CC/AHA UA/NSTEMI Guidelines (5)
lass I
pecific instructions should be given on the following: smoking cessation and achievement or maintenance of optimal weight, daily exercise, and diet (Level
f Evidence: B).
onsider the referral of patients who are smokers to a smoking cessation program or clinic and/or an outpatient cardiac rehabilitation program (Level of
vidence: A).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
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ame of Measure:
linical Rationale:
umerator:
enominator:
easure:
ate this measure on the following criteria.
Disagree
Moderate
Agreement Agree
1 2 3 4 5
seful in Improving Patient Outcomes
. Evidence-based: The scientific basis of the measure is well established. 1 2 3 4 5
. Interpretable: The results of the measure are interpretable by practitioners. 1 2 3 4 5
. Actionable: The measure addresses an area that is under the practitioner’s
control.
1 2 3 4 5
easure Design
. Denominator: The patient group to whom this measure applies
(denominator) is clinically meaningful.
1 2 3 4 5
. Numerator: The definition of conformance for this measure is clinically
meaningful.
1 2 3 4 5
. Validity:
a. The measure appears to measure what it is intended to (face validity). 1 2 3 4 5
b. The measure captures most meaningful aspects of care (content validity). 1 2 3 4 5
c. The measure correlates well with other measures of the same aspect of
care (construct validity).
1 2 3 4 5
. Reliability: The measure is likely to be reproducible across organizations
and delivery settings.
1 2 3 4 5
easure Implementation
. Feasibility:
a. The data required for the measure is likely to be obtained with
reasonable effort.
1 2 3 4 5
b. The data required for the measure is likely to be obtained at reasonable
cost.
1 2 3 4 5
c. The data required for the measure is likely to be obtained within the
period allowed for data collection.
1 2 3 4 5
verall Assessment Do Not Include Could Include Must Include
onsidering your assessment of this measure on all dimensions above, rate
his measure overall for inclusion into the ACC/AHA STEMI/NSTEMI
erformance Measurement Set.
1 2 3 4 5
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Attribute of Performance Considerations
seful in Improving Patient Outcomes
. Evidence-based: The scientific basis of the
measure is well established.
This can be confirmed by explicit reference to a published clinical practice guideline.
. Interpretable: The results of the measure are
interpretable by practitioners.
This is your assessment of the degree with which a provider can clearly understand
what the results mean and can take action if necessary.
. Actionable: The measure addresses an area that is
under the practitioner’s control.
This is your assessment of the degree with which a provider is empowered and can
influence the activities of the health care system toward improvement.
easure Design
. Denominator: The patient group to whom this
measure applies (denominator) is clinically
meaningful.
Depending upon intended use of the measure, the data source, any inclusion or
exclusion criteria, and sampling frames are explicit. These criteria used must be
clinically meaningful. An algorithm for determining the denominator may be
present.
. Numerator: The definition of conformance for this
measure is clinically meaningful.
The numerator may be specified using either explicit or implicit criteria. These
criteria used must be clinically meaningful. An algorithm for determining the
numerator may be present.
. Validity:
This can be confirmed by your judgment of the clarity and comprehensiveness of
the measure. For those measures that have been actually tested for validity, you may
see indications of specific testing such as comparisons with the results of other
methods, criterion or gold standard validity testing, and criterion validity testing.
There may also be documentation that the health care construct underlying the
measure is associated with important health care processes/outcomes.
a. The measure appears to measure what it is
intended to (face validity).
b. The measure captures most meaningful aspects
of care (content validity).
c. The measure correlates well with other measures
of the same aspect of care (construct validity).
. Reliability: The measure is likely to be
reproducible across organizations and delivery
settings.
This can be confirmed by specific tests undertaken by the measure developers. For
those measures that have been actually tested for reliability, you may see indications
of types of reliability testing such as test-retest reliability, inter-rater reliability, data
accuracy checks, and internal consistency analyses. If the measure has not been used
in practice, indicate the degree of likelihood that it is reproducible.
easure Implementation
. Feasibility: From your perspective, the required data can be typically abstracted from patient
charts or there are national registries, databases readily available. For those measures
actually being used, there is information on the data collection approach and the
system required to support the measure.
a. The data required for the measure is likely to be
obtained with reasonable effort.
b. The data required for the measure is likely to be
obtained at reasonable cost.
c. The data required for the measure is likely to be
obtained within the period allowed for data
collection.
verall Assessment
onsidering your assessment of this measure on all
imensions above, rate this measure inclusion in the
CC/AHA STEMI/NSTEMI Performance
easurement Set.
Consider a balance in the continuum of care. Consider overall purpose of the
measurement set and the intended user.
A
M
D
D
D
D
D
D
D
D
T
c
260 Krumholz et al. JACC Vol. 47, No. 1, 2006
ACC/AHA STEMI/NSTEMI Performance Measures January 3, 2006:236–65PPENDIX C. Relationships With Industry—ACC/AHA Writing Committee to Develop Performance
easures on ST-Elevation MI/Non–ST-Elevation MI
Name Research Grant Speakers Bureau/Honoraria
Stock
Ownership
Consultant/
Advisory Board
r. Harlan M. Krumholz ● Parkes-Davis/Pfizer
● Genentech
● Biogen
None None ● Astra Zeneca
● BMS/Sanofi
● CVT
r. Jeffrey L. Anderson ● Merck
● Pharmacia (Pfizer)
● Wyeth
● Berlex
● Merck
● Pfizer
None ● Aventis
● Berlex
● Merck
● Wyeth
r. Neil H. Brooks None None None ● Lilly
r. Francis M. Fesmire ● Agilent Technologies
● Cor Therapeutics
● DuPont
Radiotherapeutics
● Genentech
● Dade-Behring None None
r. Costas T. Lambrew None None None None
r. Mary Beth Landrum ● Merck None None None
r. W. Douglas Weaver None None None None
r. John Whyte None None None None
his table represents the actual or potential relationships of committee members with industry that were reported orally at the initial committee meeting and updated in
onjunction with all meetings and conference calls of the writing committee. It does not reflect any actual or potential relationships at the time of publication.
A
M
D
D
T
w
e
261JACC Vol. 47, No. 1, 2006 Krumholz et al.
January 3, 2006:236–65 ACC/AHA STEMI/NSTEMI Performance MeasuresPPENDIX D. Relationships With Industry–External Peer Reviewers for the ACC/AHA Clinical Performance
easures for Adults With ST-Elevation MI/Non–ST-Elevation MI*
Reviewer Name† Representation Research Grant
Speakers
Bureau/Honoraria
Stock
Ownership
Consultant/
Advisory Board
r. Elliott Antman ● Official Reviewer–
Chair, ACC/AHA Task
Force on Practice
Guidelines
Chair, ACC/AHA STEMI
Guideline Writing
Committee
● Aventis
● Bayer
● Biosite
● Boehringer Mannheim
● Bristol-Myers Squibb
● British Biotech
● Centor
● Cor/Millennium
● Corvas
● Dade
● Genentech
● Lilly
● Merck
● Pfizer
● Sunol
None None ● Aventis
r. Robert Califf ● Official Reviewer–
ACCF Board of Trustees
● Accumetrics
● Actelion
● Ajinomoto
● Alsius
● Amgen
● Astra Hassle
● Aventis
● Biomarin
● Biosite
● Boston Scientific
● Bracco
● Bristol-Myers Squibb
● Cambridge Heart
● Cardiodynamics
● Centocor
● Chase Medical
● Chiron
● Coagulation Diagnostics
● Corcept
● Corgentech
● Critline
● Dade Behring
● Daiichi
● Datascope
● Devco
● Elan Pharmaceuticals
● Enzon
● Esai
● Geneceutics
● Genentech
● GlaxoSmithKline
● Guidant
● Guilford
● Pharmaceuticals
● Harvard Health Care
● Hemosol
● InfraReDx
● Intracel
● IOMED
● Lincare
● Aventis
● Bristol-Myers
Squibb
● Conceptis
● GlaxoSmithKline
● Merck
● Millennium
● Novartis
● Ortho Biotech
● Paraxel
● Pennside
● Partners
● Pfizer
● Pharmacia/Upjohn
● Pharsight
● Schering Plough
● Wyeth Ayerst
None ● GlaxoSmithKline
● Pfizer
Continued on next page
his table represents the relationships of peer reviewers with industry that were disclosed at the time of peer review of this guideline. It does not necessarily reflect relationships
ith industry at the time of publication. *Participation in the peer-review process does not imply endorsement of the document. †Names are listed in alphabetical order withinach category of review.
AD
D
D
D
D
M
D
D
262 Krumholz et al. JACC Vol. 47, No. 1, 2006
ACC/AHA STEMI/NSTEMI Performance Measures January 3, 2006:236–65PPENDIX D Continued
Reviewer Name† Representation Research Grant
Speakers
Bureau/Honoraria
Stock
Ownership
Consultant/
Advisory Board
r. Robert Califf
(continued)
● Medicure
● Medivance
● Medtronic Foundation
● Merck
● Millennium
● NABI
● Novartis
● Ortho Biotech
● Otsuka
● Parke Davis
● Pfizer
● Pharmacia/Upjohn
● Pheromone Science
● Proctor and Gamble
● Promethesus
● Quanam
● Salix
● Sanofi
● Spectranetics
● St. Jude Medical
● Synaptic
● The Medicines Company
● Theravance
● Vesicor
● Vicuron
● Wyeth Ayerst
● Yamanouchi
r. Barbara Drew ● Official Reviewer–
American Heart
Association
None ● Phillips
● Inovise Medical
● Medtronic GE
None None
r. Kim A. Eagle ● Official Reviewer–
Lead Reviewer, ACC/AHA
Task Force on Performance
Measures
None None None None
r. Gregg Fonarow ● Official Reviewer–
American Heart
Association
● GSK
● Pfizer
None None ● GlaxoSmithKline
● Merck-Shering
Plough
● Pfizer
● Bristol-Myers
Squibb/Sanofi
Partnership
r. George McKendall ● Official Reviewer–
ACCF Board of Governors
None None None None
s. Janet Leiker ● Organizational Reviewer–
American Academy of
Family Physicians
None None None None
r. Martha Radford ● Content Reviewer–
Chair, ACC/AHA Task
Force on Clinical Data
Standards
None None None None
r. Rita F. Redberg ● Content Reviewer–
ACC/AHA Task Force on
Clinical Data Standards
None None None None
AD
D
D
D
D
D
D
D
D
263JACC Vol. 47, No. 1, 2006 Krumholz et al.
January 3, 2006:236–65 ACC/AHA STEMI/NSTEMI Performance MeasuresPPENDIX D Continued
Reviewer Name† Representation Research Grant
Speakers
Bureau/Honoraria
Stock
Ownership
Consultant/
Advisory Board
r. Judith Hochman ● Content Reviewer–
ACC/AHA STEMI
Guideline Writing
Committee
● Arginox Pharmaceutical
● Aventis
● Cor/Millennium
● Guidant
● Lilly
● Merck
● Daichii
● Proctor & Gamble
r. Frederick Kushner ● Content Reviewer–
ACC/AHA STEMI
Guideline Writing
Committee
● Aginamoto Co.
● Andrx Labs
● Atherogenics, Inc.
● Boehringer-Ingelheim
● Medtronic
● Novartis
● Rorer
● Schering-Plough
● Bristol-Myers
Squibb
● Merck
● Pfizer
● Reliant
● Abbott
Labs
● Baxter
● Guidant
● Medtronic
● Merck
● Pfizer
● Millennium, Inc.
r. Joseph Ornato ● Content Reviewer–
ACC/AHA STEMI
Guideline Writing
Committee
● Genentech
● Meridian Medical Corp.
● Wyeth
None None ● Bristol-Myers-
Squibb
● Genentech
● HP/Agilent
● Medtronic
● Meridian
● Medical Corp.
● Philips
● PhysioControl
● Scios
● Revivant Corp.
● Wyeth
r. Eugene Braunwald ● Content Reviewer–
Chair, ACC/AHA UA/
NSTEMI Guideline
Writing Committee
None None None None
r. Thomas Levin ● Content Reviewer–
ACC/AHA UA/NSTEMI
Guideline Writing
Committee
None None None None
r. Earl Smith III ● Content Reviewer–
ACC/AHA UA/NSTEMI
Guideline Writing
Committee
None None None None
r. Pierre Theroux ● Content Reviewer–
ACC/AHA UA/NSTEMI
Guideline Writing
Committee
None None ● Astra
Zeneca
● Aventis
● Proctor &
Gamble
None
r. Rohit Arora ● Content Reviewer–
ACCF Cardiac
Catheterization and
Intervention Committee
None ● Aventis None None
r. Carlos Ruiz ● Content Reviewer–
ACCF Cardiac
Catheterization and
Intervention Committee
● Cook Cardiology None None None
Continued on next page
AD
D
D
D
D
D
D
D
S
A
C
J
T
S
A
M
G
F
R
264 Krumholz et al. JACC Vol. 47, No. 1, 2006
ACC/AHA STEMI/NSTEMI Performance Measures January 3, 2006:236–65PPENDIX D Continued
Reviewer Name† Representation Research Grant
Speakers
Bureau/Honoraria
Stock
Ownership
Consultant/
Advisory Board
r. Karl B. Kern ● Content Reviewer–
ACCF Emergency
Cardiac Care Committee
None None None ● ERS
● Medtronic
● Revivant Corp.
r. Mary Ann Peberdy ● Content Reviewer–
ACCF Emergency
Cardiac Care Committee
None None None None
r. Michael Rosenberg ● Content Reviewer–
ACCF Emergency
Cardiac Care Committee
None None None None
r. David Faxon ● Content Reviewer–
AHA Quality of Care
and Outcomes Steering
Committee
None None None None
r. William Weintraub ● Content Reviewer–
AHA Quality of Care
and Outcomes Steering
Committee
None None None None
r. Bojan Cercek ● Content Reviewer–
AHA Committee on
Acute Cardiac Care
None None None None
r. James De Lemos ● Content Reviewer–
AHA Committee on
Acute Cardiac Care
● Aventis
● BMS/Sanofi
● Merck
None None None
r. Jose Lopez-Sendon ● Content Reviewer–
AHA Committee on
● Aventis
● BMS
None None NoneAcute Cardiac Care ● TIMI
1taff
merican College of Cardiology Foundation
hristine W. McEntee, Chief Executive Officer
oseph M. Allen, MA, Director, Clinical Decision Support
ilithia McBride, Senior Specialist, Clinical Performance
Measurement
usan L. Morrisson, Associate Specialist, Clinical Perfor-
mance Measurement
merican Heart Association
. Cass Wheeler, Chief Executive Officer
ayle R. Whitman, PhD, RN, FAAN, Vice President,
Office of Science Operations
ernando Costa, MD, FAHA, Staff Scientist
EFERENCES
1. Spertus JA, Eagle KA, Krumholz HM, Mitchell KR, Normand SL.
American College of Cardiology and American Heart Association
methodology for the selection and creation of performance measures
for quantifying the quality of cardiovascular care. J Am Coll Cardiol
2005;45:1147–56.
2. American Heart Association. Heart Disease and Stroke Statistics—
2003 update. Dallas, TX: American Heart Association, 2002.
3. Braunwald E. Acute myocardial infarction—the value of being pre-
pared. N Engl J Med 1996;334:51–2.
4. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA
guideline for the management of patients with acute myocardial
infarction: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Committee onManagement of Acute Myocardial Infarction). J Am Coll Cardiol
1999;34:890–911.
5. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002
guideline update for the management of patients with unstable angina
and non–ST-segment elevation myocardial infarction—summary arti-
cle: a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee on the
Management of Patients With Unstable Angina). J Am Coll Cardiol
2002;40:1366–74.
6. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines
for the management of patients with ST-elevation myocardial infarc-
tion—executive summary: a report of the ACC/AHA Task Force on
Practice Guidelines (Committee to Revise the 1999 Guidelines on the
Management of Patients With Acute Myocardial Infarction. J Am
Coll Cardiol 2004;44:671–719.
7. Cannon CP, Battler A, Brindis RG, et al. American College of
Cardiology key data elements and definitions for measuring the clinical
management and outcomes of patients with acute coronary syndromes:
a report of the American College of Cardiology Task Force on Clinical
Data Standards (Acute Coronary Syndromes Writing Committee).
J Am Coll Cardiol 2001;38:2114–30.
8. Smith SC Jr., Blair SN, Bonow RO, et al. AHA/ACC scientific
statement: AHA/ACC guidelines for preventing heart attack and
death in patients with atherosclerotic cardiovascular disease: 2001
update: a statement for healthcare professionals from the American
Heart Association and the American College of Cardiology. Circula-
tion 2001;104:1577–9.
9. The SOLVD Investigators. Effect of enalapril on mortality and the
development of heart failure in asymptomatic patients with reduced
left ventricular ejection fractions. N Engl J Med 1992;327:685–91.
0. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on
ischemic events after myocardial infarction. Results of the Survival and
Ventricular Enlargement trial. SAVE Investigators. Circulation 1994;90:
1731–8.
11
1
1
1
1
265JACC Vol. 47, No. 1, 2006 Krumholz et al.
January 3, 2006:236–65 ACC/AHA STEMI/NSTEMI Performance Measures1. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative
Group. ISIS-4: a randomised factorial trial assessing early oral captopril,
oral mononitrate, and intravenous magnesium sulphate in 58,050 patients
with suspected acute myocardial infarction. Lancet 1995;345:669–85.
2. Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic
significance of atrial fibrillation in acute myocardial infarction: the
GISSI-3 data. Heart 2001;86:527–32.
3. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-
converting-enzyme inhibitor zofenopril on mortality and morbidity
after anterior myocardial infarction. The Survival of Myocardial
Infarction Long-Term Evaluation (SMILE) Study Investigators.
N Engl J Med 1995;332:80–5.4. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on
life expectancy of patients with reduced left-ventricular function after
acute myocardial infarction. TRACE Study Group. Trandolapril
Cardiac Evaluation. Lancet 1999;354:9–12.
5. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality
and morbidity in high-risk patients after acute myocardial infarction:
the OPTIMAAL randomised trial. Optimal Trial in Myocardial
Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:
752–60.
6. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or
both in myocardial infarction complicated by heart failure, left ven-
tricular dysfunction, or both. N Engl J Med 2003;349:1893–906.
